Clinical Application

  • Adjunct treatment for liver diseases

    Emma:Acute viral hepatitis A. Clinical symptoms: hypodynamia, appetite loss, distension, hepatalgia; Physical sign: hepatomegaly with tenderness; Chemical test: ALT, AST, TBIL increased significantly; Etiological diagnosis: HAV-RNA existing in serum.
    Learn more
  • Adjunct treatment for chemotherapy on tumor

    Peter: Gastrointestinal carcinoma. After systemic chemotherapy for one week, severe side effects occurred, including abnormal liver function, nausea, vomiting, etc. Chemotherapy was suspended.
    Learn more

Liver Disease

Clinical data demonstrates that GSH is effective at adjunct treatments of liver diseases, such as chronic hepatic disease, viral hepatitis, alcoholic hepatic disease, hepatocirrhosis, post-traumatic hepatic injury, non-alcoholic fatty liver.
  • GSH is an effective adjunctive treatment for chronic hepatic disease

    In a multi-center clinical study involving 10 well -reputed hospitals in Shanghai, China. GSH is administered to 245 patients with a variety of liver diseases, including hepatitis induced by intoxication, alcoholic hepatitis, fatty liver, chronic viral hepatitis and active hepatitis, etc. GSH 1200mg, once daily, 3 weeks consecutively ...more

  • Lutasun is an effective agent in treatment of the patients with viral hepatitis

    The improvement rates of clinical symptoms and signs of the treatment group are significantly higher than those of control group. The differences are statistically significant ...more

  • The domestic GSH has a sound efficacy in the improvement of clinical signs and hepatic functions.

    All the 110 patients with ALD enrolled had a history of drinking over 80-12g daily for 5 years, and were randomized either into domestic GSH (continuous infusion of 600mg daily for 30d) or import GSH (with the same dosage.course and route as domestic GSH) group. The efficacy and safety were evaluated with clinical and biochemical ...more

  • GSH is an effective drug in treating the damaged liver following trauma

    A total of 128 patients with damaged liver following trauma were randomly divided into 2 groups, the patients receiving GSH for 1.2-l.8 g per day through intravenous drip for 7 days as the treatment group (n = 60) and the patients receiving inosine for l.0-2.0 g, Vitamin C for 2.0-3.0 g, kali magnesii aspartatis for 20ml and ...more

Chemotherapy on Tumor

  • The therapeutic effects of GSH on liver damage caused by chemotherapy
  • Neuroprotective Effect of Reduced Glutathione
  • GSH is effective at preventing or treating liver damage caused by chemotherapy drugs.

    Clinical data of 102 patients receiving chemotherapy were analyzed retrospectively. 17 patients was divided into treatment group with 9 males and 8 females, and with the average age of 37±s 18a. GSH (0.6~1.2g, i.v.gtt, qd×10~14d) was administrated when liver dysfunction occurred. 46 patients were divided into prevention group with 28 males and 18 females, and with the average age of 39±13a. Patients were administered with GSH 2 days before chemotherapy, with same administration method as the treatment group. 39 patients were divided into the control group with 24 males and 15 females, and with the average of 38±11a. Patients received chemotherapy drugs with no GSH.

    Reference: Mao Yaosheng. Therapeutic effect of reduced glutathione hormone on damaged liver after trauma [J]. Chinese Journal of Traumatology, 2002, 18 (5) : 287-289

  • GSH is a promising and effective new drug for the prevention of CDDP-induced neuropathy.

    50 patients with advanced gastric cancer treated with a weekly CDDP-based regimen were included. In GSH arm (25 patients), GSH was given at a dose of 1.5g/m2 in 100mL of normal saline solution before CDDP administration, and at a dose of 600mg on days 2 to 5. Normal saline solution was administered to placebo-randomized patients (25 patients).

    Reference : Stefano Cascinu, et al. Neuroprotective Effect of Reduced Glutathione on Cisplatin – Based Chemotherapy in Advanced Gastric Cancer: A Randomized Double – Blind Placebo –Controlled Trial, Journal of Clinical Oncology, Vol 13, No 1 (January), 1995: pp 26-32